- Home
- CHRS vs FLC Comparison
CHRS vs FLC Comparison
Compare CHRS & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- FLC
- Stock Information
- Founded
- CHRS 2010
- FLC 2003
- Country
- CHRS United States
- FLC United States
- Employees
- CHRS N/A
- FLC N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- FLC Trusts Except Educational Religious and Charitable
- Sector
- CHRS Health Care
- FLC Finance
- Exchange
- CHRS Nasdaq
- FLC Nasdaq
- Market Cap
- CHRS 84.2M
- FLC 174.2M
- IPO Year
- CHRS 2014
- FLC N/A
- Fundamental
- Price
- CHRS $0.90
- FLC $17.17
- Analyst Decision
- CHRS Buy
- FLC
- Analyst Count
- CHRS 3
- FLC 0
- Target Price
- CHRS $4.68
- FLC N/A
- AVG Volume (30 Days)
- CHRS 1.2M
- FLC 37.8K
- Earning Date
- CHRS 08-07-2025
- FLC 01-01-0001
- Dividend Yield
- CHRS N/A
- FLC 6.64%
- EPS Growth
- CHRS N/A
- FLC N/A
- EPS
- CHRS N/A
- FLC N/A
- Revenue
- CHRS $272,251,000.00
- FLC N/A
- Revenue This Year
- CHRS N/A
- FLC N/A
- Revenue Next Year
- CHRS $106.56
- FLC N/A
- P/E Ratio
- CHRS N/A
- FLC N/A
- Revenue Growth
- CHRS 19.87
- FLC N/A
- 52 Week Low
- CHRS $0.66
- FLC $12.62
- 52 Week High
- CHRS $2.43
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- CHRS 59.04
- FLC 68.17
- Support Level
- CHRS $0.73
- FLC $16.86
- Resistance Level
- CHRS $0.82
- FLC $17.12
- Average True Range (ATR)
- CHRS 0.04
- FLC 0.12
- MACD
- CHRS 0.02
- FLC 0.01
- Stochastic Oscillator
- CHRS 88.02
- FLC 100.00
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.